14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
BGM vs ETON: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Eton Pharmaceutcials, Inc. (ETON) is the stronger overall head-to-head candidate over BGM Group Ltd. Class A (BGM) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BGM carries a Unified Composite Score of 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin), whereas ETON carries 35.9/100 (SELL) at $60.85 (18.4x Forward P/E, 31.3% operating margin).
Composite vs. Pillar Nuance: While BGM currently prints a higher short-term Unified Composite Score (59.6/100 HOLD vs. ETON 35.9/100 SELL), ETON captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (31.3% vs. -23.4% operating margin) and revenue trajectory (+157.9% vs. +69.8% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGM vs ETON. Trailing 12-month operating profitability (BGM -23.4% vs ETON 31.3%) and valuation multiples (BGM N/M vs ETON 18.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $108.6M market capitalization and -23.4% operating margin.
OpEx & R&D Reinvestment40.3% of Rev ($19M)
90D Engineering Disclosures0 Published
ETON Moat ProfileHigh-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.8B market capitalization and 31.3% operating margin.
OpEx & R&D Reinvestment39.9% of Rev ($56M)
90D Engineering Disclosures0 Published
Investor FAQ BGM vs ETON Key Questions & Quantitative Answers
As of Nov 20, 2026, Eton Pharmaceutcials, Inc. (ETON) is the stronger overall head-to-head candidate over BGM Group Ltd. Class A (BGM) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BGM carries a Unified Composite Score of 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin), whereas ETON carries 35.9/100 (SELL) at $60.85 (18.4x Forward P/E, 31.3% operating margin). Composite vs. Pillar Nuance: While BGM currently prints a higher short-term Unified Composite Score (59.6/100 HOLD vs. ETON 35.9/100 SELL), ETON captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (31.3% vs. -23.4% operating margin) and revenue trajectory (+157.9% vs. +69.8% YoY).
ETON leads the Growth & Scale pillar: BGM posts +69.8% YoY revenue growth and +0.0% YoY earnings growth on $48M TTM revenue (16.9% gross margin, -23.4% operating margin), compared with ETON at +157.9% YoY revenue growth and -12.6% YoY earnings growth on $141M TTM revenue (71.2% gross margin, 31.3% operating margin). On trailing 12-month operating scale, BGM generates $48M in USD-normalized revenue versus $141M for ETON. In operating R&D and SG&A reinvestment, BGM deploys 40.3% of Rev ($19M) (0 90-day corporate R&D disclosures) versus 39.9% of Rev ($56M) (0 disclosures) for ETON.
ETON screens cheaper on headline valuation multiples. BGM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.3x EV/Revenue (-19.3% EBITDA margin), whereas ETON trades at 18.4x Forward P/E, 39.8x Trailing P/E, N/M PEG, and 12.3x EV/Revenue (14.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BGM (-7.4% ROE) versus ETON (90.6% ROE) capital efficiency.
In options market volatility and institutional positioning, BGM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.69β · 80% Vol realized risk). By comparison, ETON carries 343.6% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.03x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.71β · 98% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.